In her last week at AdExchanger, Senior Editor Alyssa Boyle reflects on three years of change, and stasis, in the CTV space. Then, how Ozempic is changing the marketing world.

Eli Lilly's bet on the Oscars shows the GLP-1 ad wars are heating up. - Eli Lilly. At the 2024 Academy Awards, Eli Lilly, the ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

It’s hard to watch television without seeing advertisements for compounded GLP-1 weight-loss drugs cheaper than the authentic ...

Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...

The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable semaglutide, the active ingredient in weight loss juggernauts Wegovy and ...

Ozempic, along with its sister drug Wegovy ... where unregulated websites and social media ads peddle counterfeit versions of popular weight loss medications, often with enticing discount codes.

Female-focused supplement brands claim to have cracked the code when it comes to burning fat, banishing bloating and taking control of vaginal wellness. Now, two of the biggest — Arrae and Kourtney ...

Sarah was devastated. So when, days later, her consultant rang her up offering a brand new injection – called Ozempic – that promised to treat her diabetes and help her shed the pounds ...

Ozempic (semaglutide) is a prescription medication that's approved by the US Food and Drug Administration (FDA) for both managing blood sugar in adults with type 2 diabetes and for reducing the ...

People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...